The vaccine from the Indian pharmaceutical company Bharat Biotech achieves an efficacy of 81 percent, according to preliminary results from the phase 3 studies.
The vaccine, called Covaxin, is already being administered in India.
Covaxin’s emergency approval was harshly criticized for not having preliminary data on the phase 3 trial at the time of approval. The first results now show effectiveness of 80.6 percent. Of the 25,800 people who were tracked, 43 received corona.
Of these, 36 were in the placebo group, and seven others were given the vaccine.
Bharat Biotech developed the BBV152 vaccine in collaboration with the state-owned Indian Council of Medical Research (ICMR). That is delighted with the results. “It is proof of India’s emergence as a global vaccine superpower,” said director Balram Bhagat.
In addition to Covaxin, the vaccine from Oxford and AstraZeneca is also administered in India, albeit under the local name Covishield.